Journal
JOURNAL OF IMMUNOLOGY
Volume 194, Issue 6, Pages 2587-2595Publisher
AMER ASSOC IMMUNOLOGISTS
DOI: 10.4049/jimmunol.1400326
Keywords
-
Categories
Funding
- Wellcome Trust [082030/B/07/Z, 100083/Z/12/Z]
- National Institutes of Health [R01 AI52127, U54 AI054523]
- National Health and Medical Research Council
- Wellcome Trust [100083/Z/12/Z, 082030/B/07/Z] Funding Source: Wellcome Trust
Ask authors/readers for more resources
Gene variants that disrupt TCR signaling can cause severe immune deficiency, yet less disruptive variants are sometimes associated with immune pathology. Null mutations of the gene encoding the scaffold protein Src homology 2 domain-containing leukocyte protein of 76 kDa (SLP-76), for example, cause an arrest of T cell positive selection, whereas a synthetic membrane-targeted allele allows limited positive selection but is associated with proinflammatory cytokine production and autoantibodies. Whether these and other enigmatic outcomes are due to a biochemical uncoupling of tolerogenic signaling, or simply a quantitative reduction of protein activity, remains to be determined. In this study we describe a splice variant of Lcp2 that reduced the amount of wild-type SLP-76 protein by similar to 90%, disrupting immunogenic and tolerogenic pathways to different degrees. Mutant mice produced excessive amounts of proinflammatory cytokines, autoantibodies, and IgE, revealing that simple quantitative reductions of SLP-76 were sufficient to trigger immune dysregulation. This allele reveals a dose-sensitive threshold for SLP-76 in the balance of immunity and immune dysregulation, a common disturbance of atypical clinical immune deficiencies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available